Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for clozapine-associated obesity and type 2 diabetes in treatment-resistant schizophrenia
ACTRN12615000524594Phase 4Terminated
- Sponsor
- The University of Queensland
- Start
- Mar 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exenatide in obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by The University of Queensland. Primary endpoints: Weight loss in Arm 1, Weight loss in Arm 2 and 1 more. Started Mar 2016; status: terminated.
02
Drugs
exenatide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12615000524594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000524594.